therapy, and is associated with good results. 4, [11] [12] [13] 22, 24 In this report, we present the results of endovascular stent treatment for patients with CAD that was refractory to medical therapy.
Methods

Study Population
A retrospective review of a prospectively collected database of patients who underwent CA interventions identified 43 patients in whom endovascular stent placement was attempted for treatment of 44 CADs between January 2000 and June 2009. Data were analyzed after institutional review board approval from the University at Buffalo with waiver of informed consent.
Data Collected
The data collected included patient, CAD, and treatment characteristics; outcomes; and follow-up results. The patient variables that were collected were age, sex, cause of dissection, symptoms, and previous anticoagulant therapy. For CAD, we included location, ipsilateral MCA thromboembolism, stenosis severity, aneurysm formation, evidence of intraluminal thrombus in the CA, and presence of contralateral lesions. Carotid artery locations were classified as A (only extracranial ICA), B (extracranial ICA with CCA involvement), or C (extracranial ICA with intracranial ICA involvement). Stenosis severity was categorized as 100% (occlusion), 99% (pseudoocclusion), 70%-98%, or < 70%.
Treatment characteristics included type of stent (closed cell, open cell, or both), number of stents, timing of treatment (acute [within 24 hours from symptom onset] or elective [more than 24 hours from onset]), additional treatment, and procedure-related complications. Outcome variables were immediate recanalization rate (TIMI grade; recanalization was defined as TIMI Grade 2 or 3), residual percentage of parent vessel stenosis, and mRS score at discharge (favorable score = 0-2). Followup results included any ischemic stroke event, morbidity, death, angiographic recurrence, and retreatment.
Indications for Treatment
Our strategy for the management of CAD is shown in Fig. 1 . Patients with any ischemic symptom, including TIA or amaurosis fugax, were treated on an emergency basis with endovascular stenting. Patients with no ischemic symptoms were treated with anticoagulant therapy for 3-12 months; if follow-up radiological evaluation revealed progression or no cure of the dissection, elective stenting was performed. Patients with traumatic CAD (mostly iatrogenic in nature) and severe stenosis were treated with immediate stenting to prevent acute ICA occlusion.
Stenting Technique
Patients received intravenous heparin during the stenting procedure to maintain the activated coagulation time in the range of 250-300 seconds. Patients who were not receiving previous dual antiplatelet therapy received oral loading doses (aspirin 600 mg and clopidogrel 200 mg). A 6-8 Fr guiding catheter was introduced into the proximal CCA under roadmap guidance. A microguidewire and an over-the-wire microcatheter were used to cross the lesion. Distal runs were used to determine the exact occlusion site and lesion length. The microguidewire was exchanged with the stent delivery system, and the stent was deployed. Multiple stents, when required to cover the entire length of the lesion, were deployed by telescoping techniques. Most dissections were treated with a closedcell CA stent (Wallstent or Magic Wallstent, Boston Scientific), except those in a tortuous extracranial CA or an intracranial segment. was used when easy navigation of the protection device was expected across the proximal vasculature, and/or the severity of the stenosis did not preclude passage of the protection device. A proximal protection device (Concentric [Concentric Medical]) was used for lesions in which the operator believed that crossing the lesion for distal protection was not safe or feasible. Patients with tandem MCA occlusion due to embolism were treated with intracranial mechanical thrombus disruption/embolectomy and/or pharmacological thrombolytic therapy. Intraarterial eptifibatide was used when thrombus formation was observed immediately after successful revascularization during the procedure. After endovascular treatment, intravenous systemic heparinization was continued for 24 hours, and dual antiplatelet therapy was maintained for 3 months, after which time aspirin was continued for life.
Results
Patient Characteristics
Stent placement was attempted in 43 patients with 44 total CADs during the study period. The mean patient age at presentation was 48.9 ± 14.9 years (range 13-84 years). There were 18 male and 25 female patients. Four patients had bilateral lesions, but only 1 of these patients underwent bilateral stent placement. In terms of comorbidities, 15 patients had hypertension, 5 had diabetes mellitus, 3 had a history of smoking, 8 had systemic arteriopathy, and 8 had hyperlipidemia. The series included no cases of Marfan syndrome. Fibromuscular dysplasia was diagnosed in 2 patients. Six patients had received warfarin therapy for more than 3 months. In 35 (81.4%) of the 43 cases, the CAD caused symptoms (symptomatic cases; Tables 1 and 2 
Characteristics of CAD
There were 24 lesions (54.5%) in Location A, 4 in Location B (9.1%), and 16 in Location C (36.4%; Table  1 ). Intracranial dissections included skull base lesions such as petrous and cavernous CA segment lesions. Most patients had a lesion from the cervical-to-skull-base segment. Two patients had a cervical-to-supraclinoid segment lesion; 5 patients had only a skull base lesion. Ipsilateral MCA occlusion was present in 9 (20.5%) of 44 lesions; MCA artery-to-artery embolism from an intraluminal thrombus at the CAD was present in 8 of 9 MCA occlusions, and in 1 case due to severe vasospasm after traumatic subarachnoid hemorrhage with CAD. The mean percentage of stenosis for the 44 lesions was 75.9% ± 34.0% (range 0%-100%). Stenosis severity was 100% in 15 cases (34.1%), 99% in 6 cases (13.6%), 70%-98% in 13 cases (29.5%), and < 70% in 10 cases (22.7%). Five lesions (11.4%) showed pseudoaneurysm formation, and 11 lesions (25%) had angiographic evidence of an intraluminal thrombus (all in symptomatic patients).
Treatment Characteristics
Forty-three (97.7%) of 44 lesions were successfully treated with stenting; proximal vessel tortuosity prevented navigation of the stent delivery system to the lesion in 1 case. Sixteen (37.2%) of 43 lesions were treated with a single stent, 26 lesions (60.5%) required multiple stents, and 1 lesion (2.3%) involved the placement of a single stent followed by coil embolization of an associated pseudoaneurysm. The mean number of stents deployed per patient was 2.1 ± 1.2 (range [1] [2] [3] [4] [5] [6] Table 3 ). Embolic protection devices were used during the treatment of 14 (32.6%) of 43 lesions, consisting of distal protection devices (Filterwire EZ) in 8 lesions and PercuSurge Guard Wire in 1, and a proximal protection device (Concentric) in 6 lesions (in 1 of these lesions, distal and proximal protection devices were used). Eptifibatide was administered for thrombi observed in 11 lesions (25.6%).
Seven (16.3%) of 43 patients experienced a procedurerelated complication: MCA embolism in 1 patient (2.3%), ICH in 2 patients (4.7%), worsening of dissection in 1 patient (2.3%), stent malpositioning in 1 patient (2.3%), embolic protection filter overload in 1 patient (2.3%), and filter-retrieval device fracture in 1 patient (2.3%). Two complications (4.7%) caused permanent neurological deficits: the case of minor ischemic stroke due to MCA embolism, and the case of ICH in which the patient died of pneumonia in the hospital.
Complete recanalization (TIMI Grade 3, 37 patients [84.1%]) or partial recanalization (TIMI Grade 2, 5 patients [11.4%]) was achieved in 42 (95.5%) of 44 lesions; 2 lesions could not be recanalized (TIMI Grade 1 or 0), including the lesion in which a stent could not be placed (Table 3) . Thirty-seven lesions (84.1%) showed < 10% residual parent vessel stenosis immediately after the procedure; 5 lesions (11.2%) showed 10%-50% residual stenosis without flow limitation after the initial treatment. All lesions with aneurysmal dilation showed contrast stasis in the pseudoaneurysm immediately after the therapy.
Outcomes
Immediately after therapy, the mean NIHSS score of 35 symptomatic patients was 3.1 ± 4.7 (range 0-17). At discharge, the mean mRS score for symptomatic and asymp tomatic patients was 1.1 ± 1.2 (range 0-6), including an mRS score of 0 in 26 patients (59.1%), mRS Score 1 in 4 patients (9.1%), Score 2 in 6 patients (13.6%), Score 3 in 1 patient (2.3%), Score 4 in 3 patients (6.8%), Score 5 in 2 patients (4.5%), and Score 6 in 1 patient (2.3%). Overall, 36 (83.7%) of 43 patients recovered to an mRS score ≤ 2. Outcomes were favorable (mRS score ≤ 2) for 81.3% of the spontaneous CAD group and 91.7% of the traumatic CAD group. No significant differences were found between the 2 groups.
Follow-Up
Clinical follow-up data were available for 35 patients (81.4%) with a total of 36 lesions. The mean follow-up period was 19.2 months (range 1-92 months). During this period, 2 (5.7%) of 35 symptomatic patients experienced a TIA at 3 and 11 months, respectively, after the initial treatment. The first patient suffered spontaneous CAD and the second experienced traumatic CAD. Angiography showed no in-stent restenosis, and both patients were treated medically. No patient suffered a new stroke. One patient (2.9%) had chronic progressive renal failure 7 months after the initial treatment and died. Angiographic follow-up data were available for 20 patients with a total of 21 lesions (47.7%). The mean follow-up period was 15.0 ± 15.9 months (range 1-53 months). Nineteen of 21 lesions showed no recurrence, restenosis, or pseudoaneurysm formation. Two (10%) of 21 lesions required retreatment.
One lesion was an asymptomatic, 70% in-stent restenosis treated with percutaneous transluminal angioplasty using a cutting balloon 30 months after initial treatment. The other case had asymptomatic residual aneurysm formation and was treated with additional stenting; 32 months after this procedure, a small recurrence was noted, and the patient is undergoing follow-up evaluation. * Anticoagulant therapy was unsuccessful in 3 patients who received heparin and in 4 patients who received warfarin. † Antiplatelet therapy was unsuccessful in 8 patients, all of whom received both aspirin and clopidogrel. ‡ Location: A = extracranial ICA involvement; B = extracranial ICA with CCA involvement; C = extracranial ICA with intracranial ICA involvement. § Statistical analysis performed using unpaired t-tests. Other parameters were analyzed using chi-square tests. ¶ Statistically significant.
Spontaneous Versus Traumatic CAD Lesions
the cause of CAD. No statistically significant differences were found between parameters in spontaneous and traumatic CAD groups. Table 1 summarizes the differences between the 35 symptomatic and 9 asymptomatic lesions. The mean percentage of stenosis for symptomatic lesions was greater than that for asymptomatic lesions (89.0% vs 44.9%, respectively; p < 0.0001). In particular, 100% occlusion was more often present in the symptomatic group (p = 0.0181). Aneurysm formation occurred more often with asymptomatic lesions (p = 0.0042), and previous anticoagulant therapy was more frequent in the asymptomatic group (p = 0.0236) as expected (failure of medical therapy was an indication for treatment in these patients). No statistically * acute phase = within 24 hours from symptom onset; chronic phase = > 24 hours from symptom onset. † Statistical analysis performed using unpaired t-tests. Other parameters were analyzed using chi-square tests. ‡ Statistically significant.
Symptomatic Versus Asymptomatic Lesions
significant difference was found between symptomatic and asymptomatic groups with respect to presence of intraluminal thrombus, ipsilateral MCA occlusion, number of stents placed, or intraoperative complications.
The mRS scores at discharge in symptomatic patients were 0-2 in 28 patients, 3-5 in 6 patients, and 6 in 1 patient. All 9 patients in the asymptomatic group had an mRS score of ≤ 2 at the time of discharge. There was no statistically significant difference between the 2 groups relative to outcome at discharge and follow-up.
Patients With Favorable Versus Unfavorable Outcomes
The 28 symptomatic patients with good outcomes (mRS score ≤ 2) at discharge had a significantly lower mean NIHSS score at admission compared with the 7 patients with poor outcomes (mRS Scores 3-6; NIHSS 
Discussion
Carotid artery dissections can be spontaneous or traumatic (including iatrogenic). Subintimal dissection of the CA causes vessel narrowing or occlusion. The extension of hemorrhage into the subadventitial plane fosters the formation of a dissecting pseudoaneurysm. Thrombi in and around the dissected intima can embolize distally and cause ischemia.
Endovascular stent-assisted repair has been reported in selected cases of spontaneous or traumatic CAD. According to Biondi et al., 4 the criteria for selection of candidates for stent therapy include: 1) clinical failure of medical therapy (presence of recurrent TIAs, fluctuating neurological signs, or neurological deterioration); 2) impending stroke attributable to significant stenosis/occlusion with poor collateral circulation and reduced parenchymal perfusion on the angiographic capillary phase, CT, or MR imaging studies; 3) contraindication to anticoagulation because of intracranial or systemic hemorrhage; 4) evidence of symptomatic thromboembolic occlusion of cerebral vessels; 5) contralateral CA stenosis/occlusion; 6) need for elective occlusion of the contralateral ICA for other disease; and 7) need to avoid flow increase through the anterior communicating artery because of an associated aneurysm. Our results for stenting of CAD are comparable to those reported previously. Table 4 summarizes reported cases [1] [2] [3] [4] 8, 9, 13, 14, 16, 19, 20, 22, 24 on the basis of the meta-analytical review performed by Donas et al. 11 of 62 patients with CAD who met the following criteria: 1) endoluminal repair of the CAD was the intended management strategy; 2) minimum follow-up period of 6 months; 3) diagnosis of extracranial CAD and brain ischemia based on contrastenhanced CT, MR, or angiographic imaging findings; 4) at least 1 basic outcome criterion (neurological morbidity, stent patency, endoprosthesis-related complications, and/ or total mortality rate) was stated; 5) endoluminal repair of the CAD performed during intraarterial thrombolysis was excluded; and 6) no involvement of the intracranial CA either exclusively or by extension. In their report, 63% of patients had traumatic CAD and 37% had spontaneous CAD. Symptomatic CAD (stroke, TIA, and/or amaurosis fugax) was present in 9.6% of patients. Overall, the technical success rate was 100%, complication rate was 6.5%, mean follow-up duration was 15.7 months, angiographic recurrence rate was 1.5%, clinical adverse event rate within 30 days of stenting was 11% (ischemic stroke 9.7%, TIA 1.6%), and no deaths occurred.
To our knowledge, the series reported in this paper is the largest single-center experience of endovascular treatment for CADs. In our series, there was a higher percentage of symptomatic cases (79.6%). The inclusion of 11 cases with acute MCA occlusion (25%) due to CAD and 36.4% of cases with CAD extension into an intracranial ICA segment would explain the higher percentage of symptomatic patients.
In terms of procedure-related complications, 7 events (15.9%) occurred among 44 procedures in the present series. Although this rate appears higher than that in previous reports (6.1%), 11 only 2 (4.7%) of our patients had a permanent neurological deficit due to these complications. These are difficult lesions initially in patients who failed medical therapy or had unhealed dissections that caused acute ischemia. These patients cannot be compared with patients who are traditionally treated with conservative medical therapy. Carotid artery dissection lesions have a large burden of intraluminal thrombus; any endovascular therapy has the potential for distal embolism to occur during the procedure. Embolic protection systems, including distal filter devices, distal microballoon devices, and proximal protection devices, are useful for the prevention of this technical complication. However, protection devices have stiff and bulky tips, and it is dangerous to navigate them through severely stenotic lesions burdened with intraluminal thrombus because of the potential to cause distal embolism. We recommend the use of protection devices for straight and not severely stenotic lesions. For CAD lesions with intraluminal thrombi on diagnostic angiography, a proximal protection device with blood aspiration capability is useful and preferable versus a distal protection system for reducing the risk of artery-to-artery distal embolism. Additionally, a closed-cell designed stent is recommended to avoid "cheese-grating" of the crushed thrombus against the arterial wall, which may lead to distal embolization. In some lesions in our series, tortuous vessels precluded the navigation of a closed-cell stent. For such cases, we used an open-cell stent, sometimes in combination with a closed-cell type, after the vessels had straightened out. The most important technical tip for complication avoidance is to cover the entire dissection lesion to preserve the vessel anatomy.
In our series, patients with poor outcomes (mRS Scores 3-6) had high NIHSS scores at admission and discharge, high rates of complete occlusion, and tended to be elderly. Carotid artery dissection with intracranial segment involvement or MCA occlusion is likely an important contributor to poor outcome. Not surprisingly, the asymptomatic group had good outcomes overall compared with the symptomatic group. Most asymptomatic CAD cases reported in the literature (Table 4) were initially treated with anticoagulant therapy. In some cases symptoms remained or dissections were not healed despite anticoagulant therapy. To prevent delayed embolic stroke in Fig. 3 . Case 2. Images obtained in a 49-year-old woman with a history of blunt cervical trauma sustained during a fall. Six months after the injury, she had transient right-sided hemiparesis and was transferred to our hospital. No abnormalities were seen on the initial CT scan (not shown). The left CCA angiogram shows a flow-limiting 70% stenosis with intraluminal thrombus at the cervical segment of the ICA (A) and no occlusion or stenosis in the intracranial segment (B). The patient was immediately given a loading dose of dual antiplatelet agents. With proximal protection provided by a 7 Fr Concentric balloon catheter and distal protection of the ICA and external CA provided by a PercuSurge device with blood aspiration technique, the lesion was stented using one 8 × 29 mm and one 6 × 21 mm Wallstent (C), and complete recanalization was achieved (D). The patient's symptoms disappeared completely, and she was discharged without any neurological deficits.
such cases, stenting may be justified because of its safety and effectiveness.
The limitations of our study included its retrospective nature, lack of comparative data for a conservatively treated control group, small sample size, lack of long-term follow-up, and incomplete follow-up data. A prospective, randomized, controlled study with a significant long-term follow-up duration will be needed to assess the safety and efficacy of CAD stenting.
Conclusions
We have reported the results of initial treatment and a follow-up review of endovascular stenting for CAD at our center. This is the largest single-center experience with endovascular therapy for CADs reported to date. The overall success rate was high, and morbidity and mortality rates were acceptable. Our study demonstrates the feasibility of this treatment paradigm in spontaneous and traumatic CADs. A prospective, randomized, controlled study to assess the role of endovascular therapy in CAD is needed. 
